Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 8/2018

28.05.2018 | Original Article – Clinical Oncology

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial

verfasst von: Christina Schaub, Sied Kebir, Nina Junold, Elke Hattingen, Niklas Schäfer, Joachim P. Steinbach, Astrid Weyerbrock, Peter Hau, Roland Goldbrunner, Michael Niessen, Frederic Mack, Moritz Stuplich, Theophilos Tzaridis, Oliver Bähr, Rolf-Dieter Kortmann, Uwe Schlegel, Friederike Schmidt-Graf, Veit Rohde, Christian Braun, Mathias Hänel, Michael Sabel, Rüdiger Gerlach, Dietmar Krex, Claus Belka, Hartmut Vatter, Martin Proescholdt, Ulrich Herrlinger, Martin Glas

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

We evaluated patterns of tumor growth in patients with newly diagnosed MGMT-non-methylated glioblastoma who were assigned to undergo radiotherapy in conjunction with bevacizumab/irinotecan (BEV/IRI) or standard temozolomide (TMZ) within the randomized phase II GLARIUS trial.

Methods

In 142 patients (94 BEV/IRI, 48 TMZ), we reviewed magnetic resonance imaging scans at baseline and first tumor recurrence. Based on contrast-enhanced T1-weighted and fluid-attenuated inversion recovery images, we assessed tumor growth patterns and tumor invasiveness. Tumor growth patterns were classified as either multifocal or local at baseline and recurrence; at first recurrence, we additionally assessed whether distant lesions appeared. Invasiveness was determined as either diffuse or non-diffuse. Associations with treatment arms were calculated using Fisher’s exact test.

Results

At baseline, 115 of 142 evaluable patients (81%) had a locally confined tumor. Between treatment arms, there was no significant difference in the fraction of tumors that changed from an initially local tumor growth pattern to a multifocal pattern (12 and 13%, p = 0.55). Distant lesions appeared in 17% (BEV/IRI) and 13% (TMZ) of patients (p = 0.69). 15% of patients in the BEV/IRI arm and 8% in the TMZ arm developed a diffuse growth pattern from an initially non-diffuse pattern (p = 0.42).

Conclusions

The tumor growth and invasiveness patterns do not differ between BEV/IRI and TMZ-treated MGMT-non-methylated glioblastoma patients in the GLARIUS trial. BEV/IRI was not associated with an increased rate of multifocal, distant, or highly invasive tumors at the time of recurrence.
Literatur
Zurück zum Zitat Berkman RA, Merrill MJ, Reinhold WC et al (1993) Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153–159CrossRefPubMedPubMedCentral Berkman RA, Merrill MJ, Reinhold WC et al (1993) Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153–159CrossRefPubMedPubMedCentral
Zurück zum Zitat Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New Engl J Med 370:709–722CrossRefPubMed Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New Engl J Med 370:709–722CrossRefPubMed
Zurück zum Zitat Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740CrossRefPubMed Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740CrossRefPubMed
Zurück zum Zitat Herrlinger U, Schafer N, Steinbach JP et al (2016) Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 34:1611–1619CrossRefPubMed Herrlinger U, Schafer N, Steinbach JP et al (2016) Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. J Clin Oncol 34:1611–1619CrossRefPubMed
Zurück zum Zitat Iwamoto FM, Abrey LE, Beal K et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206CrossRefPubMedPubMedCentral Iwamoto FM, Abrey LE, Beal K et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206CrossRefPubMedPubMedCentral
Zurück zum Zitat Kunkel P, Ulbricht U, Bohlen P et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628PubMed Kunkel P, Ulbricht U, Bohlen P et al (2001) Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 61:6624–6628PubMed
Zurück zum Zitat Lamszus K, Brockmann MA, Eckerich C et al (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11:4934–4940CrossRefPubMed Lamszus K, Brockmann MA, Eckerich C et al (2005) Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin Cancer Res 11:4934–4940CrossRefPubMed
Zurück zum Zitat Narayana A, Kelly P, Golfinos J et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173–180CrossRefPubMed Narayana A, Kelly P, Golfinos J et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173–180CrossRefPubMed
Zurück zum Zitat Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787CrossRefPubMed Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787CrossRefPubMed
Zurück zum Zitat Nowosielski M, Wiestler B, Goebel G et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82:1684–1692CrossRefPubMed Nowosielski M, Wiestler B, Goebel G et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82:1684–1692CrossRefPubMed
Zurück zum Zitat Ostrom QT, Gittleman H, Liao P et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1-63CrossRefPubMed Ostrom QT, Gittleman H, Liao P et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 4):iv1-63CrossRefPubMed
Zurück zum Zitat Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231CrossRefPubMedPubMedCentral Paez-Ribes M, Allen E, Hudock J et al (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15:220–231CrossRefPubMedPubMedCentral
Zurück zum Zitat Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848CrossRefPubMed Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848CrossRefPubMed
Zurück zum Zitat Pope WB, Xia Q, Paton VE et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432–437CrossRefPubMed Pope WB, Xia Q, Paton VE et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432–437CrossRefPubMed
Zurück zum Zitat Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314CrossRefPubMedPubMedCentral Rubenstein JL, Kim J, Ozawa T et al (2000) Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2:306–314CrossRefPubMedPubMedCentral
Zurück zum Zitat Schaub C, Greschus S, Seifert M et al (2013) FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 85:191–195CrossRefPubMed Schaub C, Greschus S, Seifert M et al (2013) FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 85:191–195CrossRefPubMed
Zurück zum Zitat Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed
Zurück zum Zitat Vredenburgh JJ, Desjardins A, Herndon JE (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729 nd, et al.CrossRefPubMed Vredenburgh JJ, Desjardins A, Herndon JE (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729 nd, et al.CrossRefPubMed
Zurück zum Zitat Wick A, Dorner N, Schafer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586–592CrossRefPubMed Wick A, Dorner N, Schafer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586–592CrossRefPubMed
Zurück zum Zitat Wick W, Chinot OL, Bendszus M et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18:1434–1441CrossRefPubMedPubMedCentral Wick W, Chinot OL, Bendszus M et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18:1434–1441CrossRefPubMedPubMedCentral
Zurück zum Zitat Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336CrossRefPubMed Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336CrossRefPubMed
Metadaten
Titel
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial
verfasst von
Christina Schaub
Sied Kebir
Nina Junold
Elke Hattingen
Niklas Schäfer
Joachim P. Steinbach
Astrid Weyerbrock
Peter Hau
Roland Goldbrunner
Michael Niessen
Frederic Mack
Moritz Stuplich
Theophilos Tzaridis
Oliver Bähr
Rolf-Dieter Kortmann
Uwe Schlegel
Friederike Schmidt-Graf
Veit Rohde
Christian Braun
Mathias Hänel
Michael Sabel
Rüdiger Gerlach
Dietmar Krex
Claus Belka
Hartmut Vatter
Martin Proescholdt
Ulrich Herrlinger
Martin Glas
Publikationsdatum
28.05.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2018
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-018-2671-z

Weitere Artikel der Ausgabe 8/2018

Journal of Cancer Research and Clinical Oncology 8/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.